- Journal List
- Infect Immun
- v.67(5); 1999 May
- PMC116014
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Infect Immun. 1999 May; 67(5): 2624–2626.
PMCID: PMC116014
PMID: 10225931
Note
Geoffrey W. de Lisle,* Theresa Wilson, Desmond M. Collins, and Bryce M. Buddle
Editor: S. H. E. Kaufmann
Author information Article notes Copyright and License information PMC Disclaimer
Abstract
Four nutritionally impaired strains of Mycobacterium bovis produced by illegitimate recombination were tested for their ability to protect guinea pigs against intratracheal challenge with virulent M. bovis. All four strains and M. bovis BCG induced significant levels of protection as measured by the reduced spread of infection to the spleen and liver. In animals vaccinated with BCG or two of the other strains, the bacterial counts from the lungs were significantly lower than those of the nonvaccinated animals.
Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex, is the principal cause of tuberculosis in domestic animals and can produce human disease which is indistinguishable from that caused by M. tuberculosis. M. bovis and M. tuberculosis are genetically very similar (15), and the widely used human tuberculosis vaccine, BCG, is an M. bovis strain that became attenuated for unknown reasons during extended subculturing. In many industrialized countries, M. bovis has been eradicated from cattle or reduced to very low levels through the implementation of control programs based on test-and-slaughter principles. Bovine tuberculosis continues to be a major problem in countries which cannot afford such programs or where these programs have been only partially effective due to wildlife reservoirs of infection (12). Important reservoirs of M. bovis infection include the badger in the United Kingdom and the brushtail possum in New Zealand. In these countries, vaccination is being investigated in order to achieve more effective control of the disease (1, 4, 11). The variable effectiveness of the currently available vaccine reduces its usefulness for controlling bovine tuberculosis in cattle or wildlife (5, 12) and necessitates the development of a better vaccine. A better tuberculosis vaccine for animals will likely also have application for use in humans.
Four nutritionally impaired strains of M. bovis were selected, from a group of 440 M. bovis mutants produced by illegitimate recombination, on the basis of their inability to grow in minimal medium (16). The strains were shown to be avirulent for guinea pigs following the subcutaneous inoculation of 106 CFU. In the present study, we examined the potential of these strains to protect guinea pigs against subsequent intratracheal challenge with a virulent M. bovis strain (WAg201) originally isolated from a cow and previously used in this laboratory (17). Groups of four to eight Duncan-Hartley guinea pigs weighing 700 to 900 g were vaccinated by subcutaneous injection in the right flank with 105 CFU of either one of the nutritionally impaired strains or BCG. A control group of 10 animals was not vaccinated. Eight weeks postvaccination, all animals were each anesthetised by an intramuscular injection of 3 mg of ketamine hydrochloride (Parnell Laboratories, Auckland, New Zealand) per kg of body weight and 2.5 mg of xylazine hydrochloride (Rompun; Bayer, Auckland, New Zealand) per kg. Then they were challenged with 102 CFU (0.1 ml) of virulent M. bovis WAg201 introduced through the mouth into the trachea via a cannula. As an additional control, 105 CFU of each nutritionally impaired strain was inoculated subcutaneously into three guinea pigs that were not challenged.
All animals were sacrificed 13 weeks after vaccination. The following parameters of infection were measured: the number and distribution of macroscopic and microscopic lesions, the weights of the spleens, and the number of M. bovis CFU present in the lungs, spleen, and liver. M. bovis CFU were determined by a plate count procedure. Delayed-type hypersensitivity to tuberculin was measured immediately before vaccination and prior to sacrifice. Bovine purified protein derivative (4 U; Ministry of Agriculture and Forestry, Central Animal Health Laboratory, Auckland, New Zealand) was injected intradermally, and the diameter of the erythema was measured 24 h later. No delayed-type hypersensitivity reactions were observed when the animals were tested prior to being inoculated with mycobacteria. There were no statistical differences as determined by an analysis of variance (ANOVA) among the skin test responses of the groups of challenged animals, including the nonvaccinated group, when they were examined immediately prior to being sacrificed. The responses ranged from 12.9 to 20 mm in diameter.
Macroscopic lesions consistent with tuberculosis were observed in the lungs of the guinea pigs challenged with virulent M. bovis, and affected portions were cultured. Tissue samples for histology and bacteriology were taken from the left and right lobes of the liver, and a transverse section through the middle of the spleen was taken for histological examination. Bacteriological results for the lungs and liver are expressed as CFU/gram of tissue, and those for the spleens are expressed as CFU/spleen. The results of the vaccination experiment are summarized in Tables Tables11 and and22 and Fig. Fig.1.1. The four nutritionally impaired strains and BCG all gave significant levels of protection (P < 0.05) as measured by spleen weights (data not shown), number of macroscopic and microscopic spleen and liver lesions, and number of M. bovis CFU isolated from the spleen and liver. Analyses of spleen weights and numbers of macroscopic and microscopic lesions were undertaken with ANOVA of raw data, while analyses of bacterial counts were conducted with ANOVA of log10-transformed data. Significant differences in lung CFU were observed between the nonvaccinated group and the groups vaccinated with either BCG or one of the nutritionally impaired strains WAg520 and WAg522.
TABLE 1
Vaccine-induced protection of guinea pigs as measured by M. bovis CFUa
| Immunization group (no. of animals) | Lung | Spleen | Liver | |||
|---|---|---|---|---|---|---|
| Log10 CFU (mean ± SE) | Log10 protection | Log10 CFU (mean ± SE) | Log10 protection | Log10 CFU (mean ± SE) | Log10 protection | |
| Nonvaccinated (10) | 5.27 ± 0.1 | 0 A | 5.04 ± 0.19 | 0 A | 3.17 ± 0.17 | 0 A |
| BCG (8) | 4.33 ± 0.21 | 0.94 B | 1.76 ± 0.38 | 3.28 BC | 0.8 ± 0.09 | 2.38 C |
| WAg520 (6) | 4.35 ± 0.32 | 0.92 B | 1.21 ± 0.36 | 3.83 C | 0.7 ± 0 | 2.47 C |
| WAg521 (5) | 4.34 ± 0.28 | 0.92 AB | 3.3 ± 0.09 | 1.74 B | 1.84 ± 0.26 | 1.33 B |
| WAg522 (4) | 3.98 ± 0.12 | 1.28 B | 1.87 ± 0.61 | 3.17 BC | 0.7 ± 0 | 2.48 C |
| WAg523 (5) | 4.39 ± 0.22 | 0.88 AB | 2.35 ± 0.55 | 2.69 BC | 0.95 ± 0.14 | 2.23 C |
Open in a separate window
aValues within columns followed by the same letter are not significantly different (P > 0.05). The minimum detectable level was 0.7 log10.
TABLE 2
Vaccine-induced protection in guinea pigs as measured by macroscopic lesionsa
| Immunization group (no. of animals) | No. (mean ± SE) of: | |
|---|---|---|
| Spleen lesions | Liver lesions | |
| Nonvaccinated (10) | 118 ± 8.92 A | 263.5 ± 123.6 A |
| BCG (8) | 1.75 ± 0.88 B | 0.38 ± 0.38 B |
| WAg520 (6) | 0.33 ± 0.21 B | 0.0 ± 0.0 B |
| WAg521 (5) | 4.20 ± 1.59 B | 0.0 ± 0.0 B |
| WAg522 (4) | 0.25 ± 0.25 B | 0.0 ± 0.0 B |
| WAg523 (5) | 8.20 ± 5.69 B | 3.0 ± 3.0 B |
Open in a separate window
aValues within columns followed by the same letter are not significantly different (P > 0.05).
FIG. 1
Microscopic granuloma in spleen (▧) and liver (□) for vaccinated and control guinea pigs 5 weeks after challenge with virulent M. bovis strains. A granuloma was defined as a discrete accumulation of cells consisting predominantly of macrophages.
No macroscopic or microscopic lesions were observed in the spleens, livers, or lungs of the control animals that were vaccinated with the nutritionally impaired strains but were not challenged with virulent M. bovis. No M. bovis organisms were isolated from the spleens of these animals. These results are comparable to those of our earlier study of virulence, in which a 10-fold-higher dose was inoculated (16).
The results of this study support the use of nutritionally impaired strains as vaccines for tuberculosis. All four nutritionally impaired strains and BCG gave significant levels of protection, as demonstrated by the reduced spread of infection to the spleen and liver. A significant reduction in the bacterial lung counts, compared with those in the unvaccinated animals, was also observed in the guinea pigs vaccinated with two of the nutritionally impaired strains and BCG. The recent study of Baldwin et al. (3) demonstrated that certain vaccine strategies against M. tuberculosis may reduce the bacterial burden but exacerbate pulmonary pathology. A limitation of our study was that material was not available to determine whether the nutritionally impaired mutants influenced the development of necrotizing lesions in the lungs.
Despite its drawbacks, BCG remains the standard against which all new vaccines will ultimately be measured. Currently, no subunit or DNA vaccine has been shown in animal experiments to induce greater levels of protection against tuberculosis than BCG, and in most cases they provide less protection than BCG (2, 6, 13). These nonliving vaccines also have the disadvantage of requiring multiple vaccinations, in contrast to BCG (3, 8, 9) and the nutritionally impaired strains examined in this study. A concern about live tuberculosis vaccines is that the organisms may multiply unchecked in some immunocompromised animals. A recent study by Guleria et al. (7) has shown that nutritionally impaired leuD mutants of BCG have the potential to be safe even in very immunocompromised animals, such as SCID mice.
A notable feature of three of the nutritionally impaired strains and BCG is that compared to M. tuberculosis, they have major DNA deletions of between 10 and 65 kb (10, 14, 16). These large deletions do not all occur in the same place in the chromosome, indicating that there are many genes which are not required for in vitro growth but are essential for the maintenance of virulence. The remaining nutritionally impaired strain, WAg520, has only a 2-bp deletion in a possible undecaprenol kinase gene, and this strain was one of two nutritionally impaired strains which produced significant protection in the lungs. In contrast to BCG, the nutritionally impaired strains have genetic changes that have been found by identifying alterations to the parent strain. Although some major deletions of DNA in BCG have been identified (10, 14), the possibility of smaller genetic changes has not been excluded. In the absence of the parent strain of BCG or the complete genome sequence of BCG, the identification of all such changes will be difficult. New live vaccines against tuberculosis are likely to be acceptable for routine use only if their genetic changes have been precisely defined. While the major challenge remains identifying the portions of the chromosome which can be inactivated to produce the safest and most efficacious tuberculosis vaccine, the results of this study demonstrate the potential of nutritionally impaired strains of members of the M. tuberculosis complex to be effective and safe vaccines against tuberculosis.
Acknowledgments
We thank Lillian Morrison for statistical analysis.
This study was supported by grants from the Foundation of Research Science and Technology and MAF Policy, New Zealand.
REFERENCES
1. Aldwell F E, Pfeffer A, de Lisle G W, Jowett G, Heslop J, Keen D, Thompson A, Buddle B M. Effectiveness of BCG vaccination in protecting possums against bovine tuberculosis. Res Vet Sci. 1995;58:90–95. [PubMed] [Google Scholar]
2. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun. 1994;62:2536–2544. [PMC free article] [PubMed] [Google Scholar]
3. Baldwin S L, D’Souza C, Roberts A D, Kelly B P, Frank A A, Lui M A, Ulmer J B, Huygen K, McMurray D M, Orme I M. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun. 1998;66:2951–2959. [PMC free article] [PubMed] [Google Scholar]
4. Buddle B M, de Lisle G W, Pfeffer A, Aldwell F E. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine. 1995;13:1123–1130. [PubMed] [Google Scholar]
5. Buddle B M, Aldwell F E, Wedlock D N. Vaccination of cattle and possums against bovine tuberculosis. In: Griffin F, de Lisle G, editors. Tuberculosis in wildlife and domestic animals. Otago Conference Series 3. Dunedin, New Zealand: Otago University Press; 1995. pp. 111–115. [Google Scholar]
6. Ellner J J. The immune response in human tuberculosis—implications for tuberculosis control. J Infect Dis. 1997;176:1351–1359. . (Review.) [PubMed] [Google Scholar]
7. Guleria I, McAdam R A, Kaplan G, Jacobs W R, Jr, Bloom B R. Auxotrophic vaccines for tuberculosis. Nat Med. 1996;2:334–337. [PubMed] [Google Scholar]
8. Horwitz M A, Lee B-W E, Dillon B J, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 1995;92:1530–1534. [PMC free article] [PubMed] [Google Scholar]
9. Huygen K, Content J, Denis O, Montgomery D L, Yawman A M, Deck R R, deWitt C, Orme I M, Baldwin S, D’Souza C, Drowart A, Lozes E, Vandenbussche P, van Vooren J-P, Lui M A, Ulmer J B. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 1996;2:893–898. [PubMed] [Google Scholar]
10. Mahairas G G, Sabo P J, Hickey M J, Singh D C, Stover C K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996;178:1274–1282. [PMC free article] [PubMed] [Google Scholar]
11. Newell D G, Hewinson R G. Control of bovine tuberculosis by vaccination. Vet Rec. 1995;136:459–463. [PubMed] [Google Scholar]
12. O’Reilly L M, Daborn C J. The epidemiology of Mycobacterium bovis infection in animals and man: a review. Tubercle Lung Dis. 1995;76(Suppl. 1):1–46. [PubMed] [Google Scholar]
13. Orme I M. Progress in the development of new vaccines against tuberculosis. Int J Tuberc Lung Dis. 1997;1:95–100. [PubMed] [Google Scholar]
14. Philipp W J, Nair S, Guglielmi G, Lagranderie M, Gicquel B, Cole S T. Physical mapping of Mycobacterium bovis BCG Pasteur reveals differences from the genome map of Mycobacterium tuberculosis H37Rv and from M. bovis. Microbiology. 1996;142:3135–3145. [PubMed] [Google Scholar]
15. Sreevatsan S, Pan X, Musser J M. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA. 1997;94:9869–9874. [PMC free article] [PubMed] [Google Scholar]
16. Wilson T, Wards B J, White S J, Skou B, de Lisle G W, Collins D M. Production of avirulent Mycobacterium bovis strains by illegitimate recombination with deoxyribonucleic acid fragments containing an interrupted ahpC gene. Tubercle Lung Dis. 1997;78:229–235. [PubMed] [Google Scholar]
17. Wilson T M, de Lisle G W, Collins D M. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol. 1995;15:1009–1015. [PubMed] [Google Scholar]
Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)
